<DOC>
	<DOC>NCT01223378</DOC>
	<brief_summary>The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.</brief_summary>
	<brief_title>Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects must have a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OH) in one or both eyes. Subjects with a known hypersensitivity or contraindications to latanoprost or any of the ingredients in the study drugs. Subjects with closed or barely open anterior chamber angle or a history of acute angle closure in either eye.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>